JOHANNESBURG, March 8 (Reuters) - South Africa’s Aspen Pharmacare said on Thursday first-half earnings rose 26 percent, buoyed by a strong result from therapeutic focused brands.
Aspen, with presence in 50 countries spanning six continents, said normalised headline earnings per share (HEPS) for the six-months ended Dec.31, rose to 872 cents from 692 cents.
HEPS is the main profit gauge in South Africa, which strips out certain one-off items.
Group revenue grew 11 percent to 21.9 billion rand ($1.85 billion) from 19.8 billion rand.
$1 = 11.8355 rand Reporting by Nqobile Dludla; Editing by Biju Dwarakanath